BioWorld

July 26, 2007

Merck Paying $350M In Stock For Acquisition Of NovaCardia

NovaCardia Inc., which has a Phase III product for congestive heart failure, is being acquired by Merck & Co. Inc. for $350 million in stock. (BioWorld Today) Read More

Amid Fallout From Panel Vote, Spectrum Signs License Deal

Cell Therapeutics Gets Phase II Cancer Drug In SMi Acquisition

Imarx Goes Public With $15M Offering; Archemix Files For IPO

Genzyme Beats Q2 Estimates On Higher Than Expected Revenue

Other News To Note

AIDS Clinic Roundup

Clinic Roundup

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...

New mechanism of action identified for QC-6352

BioWorld Science

QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...